Cancer pharmacogenetics
Methods in Molecular Biology, ISSN: 1064-3745, Vol: 448, Page: 437-446
2008
- 4Citations
- 34Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Cancer pharmacogenetics is a burgeoning field. There are now many published associations between genotype and outcome or toxicity from chemotherapy treatment. Performing pharmacogenetics studies in cancer requires careful consideration of the sample type to be used (germline vs tumor); the genotyping platform to be used (medium, low, or high throughput); and the analysis and reporting of associations and observations. © 2008 Humana Press, a part of Springer Science + Business Media, LLC.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84934439748&origin=inward; http://dx.doi.org/10.1007/978-1-59745-205-2_15; http://www.ncbi.nlm.nih.gov/pubmed/18370241; http://link.springer.com/10.1007/978-1-59745-205-2_15; https://dx.doi.org/10.1007/978-1-59745-205-2_15; https://link.springer.com/protocol/10.1007/978-1-59745-205-2_15; http://www.springerlink.com/index/10.1007/978-1-59745-205-2_15; http://www.springerlink.com/index/pdf/10.1007/978-1-59745-205-2_15
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know